PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat infections in chronic and acute wounds, announced today it has entered into a new strategic partnership with V&M Industries, Inc. for non-exclusive rights to market Microcyn-based skin and wound care over-the-counter products in the United States and Canada while providing Oculus with a significant percentage of those revenues.
